基于治疗反应的多重戒烟药物调整在黑人吸烟成人中的随机临床试验
这项随机临床试验在密苏里州堪萨斯城一家联邦合格健康中心纳入392名非西班牙裔黑人每日吸烟成人,比较基于治疗反应的药物调整方案(ADT,196人)与增强常规护理(UC,196人),两组均接受18周药物治疗并随访至第26周。ADT组先使用尼古丁贴片,第2周根据一氧化碳验证的吸烟状态(CO≥6 ppm)首次转换为伐尼克兰,必要时第6周再次转换为安非他酮+尼古丁贴片。意向性分析显示,第12周(ADT 17.4% vs UC 11.7%;OR 1.58;95%CI 0.89-2.80;P=.12)、第18周(16.3% vs 15.8%;OR 1.04;95%CI 0.61-1.78;P=.89)和第26周(12.2% vs 13.3%;OR 0.91;95%CI 0.50-1.65;P=.76)验证的7天戒断率均无显著差异。第2周对治疗有反应且CO验证戒断者,第12周戒断的 odds 是未反应者的4.6倍(28.7% vs 7.8%;OR 4.6;95%CI 2.5-8.6;P<.001)。
要点
- ADT组与UC组第12周验证7天戒断率分别为17.4%(34/196)与11.7%(23/196),OR 1.58(95%CI 0.89-2.80;P=.12),无显著差异。
- 第18周戒断率ADT 16.3%(32/196)vs UC 15.8%(31/196),OR 1.04(95%CI 0.61-1.78;P=.89);第26周ADT 12.2%(24/196)vs UC 13.3%(26/196),OR 0.91(95%CI 0.50-1.65;P=.76)。
- ADT组中接受药物调整者135/188(71.8%),其中第12周戒断11/135(8.1%)。
- 控制治疗分组后,第2周对治疗有反应且CO验证戒断者第12周戒断率为28.7%(37/129),未反应者为7.8%(19/245),OR 4.6(95%CI 2.5-8.6;P<.001)。
- 作者认为,早期治疗反应是抢先干预的重要领域。
适用人群与场景
- 非西班牙裔黑人每日吸烟成人,在密苏里州堪萨斯城一家联邦合格健康中心招募,2019年5月至2022年1月开展。
- 平均(SD)年龄53(11.6)岁;女性224例(57%);186例(47%)收入≤联邦贫困线100%;平均(SD)每日吸烟13(12.4)支。
诊断标准与关键阈值
- 一氧化碳(CO)验证的吸烟状态:CO≥6 ppm 作为判断未戒烟并触发药物调整的阈值。
- 戒断采用阿那巴辛(anabasine)验证和安那他品(anatabine)验证的时点戒断率。
处置流程与药物剂量
- 两组均接受18周药物治疗,随访至第26周。
- ADT组(196人):接受尼古丁贴片(NP),并根据第2周CO验证吸烟状态(CO≥6 ppm)首次转换为伐尼克兰;若需要,根据第6周CO验证吸烟状态(CO≥6 ppm)第二次转换为安非他酮+尼古丁贴片(bupropion + NP),最多2次药物调整。
- UC组(196人):整个治疗期间持续接受尼古丁贴片。
研究设计与关键结果
- 随机临床试验,392名参与者(ADT组196人,UC组196人),324人(83%)完成试验。
- 主要终点第12周验证7天戒断率:ADT 34/196(17.4%)vs UC 23/196(11.7%);OR 1.58(95%CI 0.89-2.80;P=.12),无显著差异。
- 次要终点第18周:ADT 32/196(16.3%)vs UC 31/196(15.8%);OR 1.04(95%CI 0.61-1.78;P=.89),无显著差异。
- 次要终点第26周:ADT 24/196(12.2%)vs UC 26/196(13.3%);OR 0.91(95%CI 0.50-1.65;P=.76),无显著差异。
- ADT组中接受药物调整者135/188(71.8%),其中第12周戒断11/135(8.1%)。
- 控制治疗分组后,第2周对治疗有反应且CO验证戒断者第12周戒断37/129(28.7%),未反应者19/245(7.8%);OR 4.6(95%CI 2.5-8.6;P<.001)。
- 第12周戒断的事后敏感性分析采用多重插补,以单调逻辑回归、治疗和性别为协变量插补缺失数据。
证据类型、等级与局限
- 证据类型:随机临床试验(adapted therapy vs enhanced usual care)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于每日吸烟的黑人成人,尼古丁贴片单药失败后转换为伐尼克兰和/或安非他酮+尼古丁贴片,与继续尼古丁贴片相比未显著改善第12、18、26周戒断率。
- 作者认为,研究前2周内达到戒断者 later 戒断可能性显著更高,早期治疗反应是抢先干预的重要领域。
指南或共识出处
- JAMA Network Open 发表的随机临床试验;试验注册号 ClinicalTrials.gov NCT03897439。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Adapting to different smoking cessation medications when an individual has not stopped smoking has shown promise, but efficacy has not been tested in racial and ethnic minority individuals who smoke and tend to have less success in quitting and bear a disproportionate share of tobacco-related morbidity and mortality.
OBJECTIVE: To evaluate efficacy of multiple smoking cessation pharmacotherapy adaptations based on treatment response in Black adults who smoke daily.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial of adapted therapy (ADT) or enhanced usual care (UC) included non-Hispanic Black adults who smoke and was conducted from May 2019 to January 2022 at a federally qualified health center in Kansas City, Missouri. Data analysis took place from March 2022 to January 2023.
INTERVENTIONS: Both groups received 18 weeks of pharmacotherapy with long-term follow-up through week 26. The ADT group consisted of 196 individuals who received a nicotine patch (NP) and up to 2 pharmacotherapy adaptations, with a first switch to varenicline at week 2 and, if needed, a second switch to bupropion plus NP (bupropion + NP) based on carbon monoxide (CO)-verified smoking status (CO ≥6 ppm) at week 6. The UC group consisted of 196 individuals who received NP throughout the duration of treatment.
MAIN OUTCOMES AND MEASURES: Anabasine-verified and anatabine-verified point-prevalence abstinence at week 12 (primary end point) and weeks 18 and 26 (secondary end points). The χ2 test was used to compare verified abstinence at week 12 (primary end point) and weeks 18 and 26 (secondary end points) between ADT and UC. A post hoc sensitivity analysis of smoking abstinence at week 12 was performed with multiple imputation using a monotone logistic regression with treatment and gender as covariates to impute the missing data.
RESULTS: Among 392 participants who were enrolled (mean [SD] age, 53 [11.6] years; 224 [57%] female; 186 [47%] ≤ 100% federal poverty level; mean [SD] 13 [12.4] cigarettes per day), 324 (83%) completed the trial. Overall, 196 individuals were randomized to each study group. Using intent-to-treat and imputing missing data as participants who smoke, verified 7-day abstinence was not significantly different by treatment group at 12 weeks (ADT: 34 of 196 [17.4%]; UC: 23 of 196 [11.7%]; odds ratio [OR], 1.58; 95% CI, 0.89-2.80; P = .12), 18 weeks (ADT: 32 of 196 [16.3%]; UC: 31 of 196 [15.8%]; OR, 1.04; 95% CI, 0.61-1.78; P = .89), and 26 weeks (ADT: 24 of 196 [12.2%]; UC: 26 of 196 [13.3%]; OR, 0.91; 95% CI, 0.50-1.65; P = .76). Of the ADT participants who received pharmacotherapy adaptations (135/188 [71.8%]), 11 of 135 (8.1%) were abstinent at week 12. Controlling for treatment, individuals who responded to treatment and had CO-verified abstinence at week 2 had 4.6 times greater odds of being abstinent at week 12 (37 of 129 [28.7%] abstinence) than those who did not respond to treatment (19 of 245 [7.8%] abstinence; OR; 4.6; 95% CI, 2.5-8.6; P < .001).
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of adapted vs standard of care pharmacotherapy, adaptation to varenicline and/or bupropion + NP after failure of NP monotherapy did not significantly improve abstinence rates for Black adults who smoke relative to those who continued treatment with NP. Those who achieved abstinence in the first 2 weeks of the study were significantly more likely to achieve later abstinence, highlighting early treatment response as an important area for preemptive intervention.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03897439.
参考来源
- Nollen NL, Ahluwalia JS, Mayo MS, et al. Multiple Pharmacotherapy Adaptations for Smoking Cessation Based on Treatment Response in Black Adults Who Smoke: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37338906. doi:10.1001/jamanetworkopen.2023.17895
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。